DeepMed Research

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

Phase 3

Not yet recruiting

Conditions: Lung Non-Small Cell Carcinoma
Stage IIIB Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Ceralasertib
Biological: Durvalumab
Procedure: Echocardiography Test

First Posted Date: 2024-12-13

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 630

Registration Number: NCT06732401

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

Phase 2

Not yet recruiting

Conditions: Barrett Esophagus
Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8
Clinical Stage I Esophageal Adenocarcinoma AJCC v8
Esophageal Adenocarcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Endoscopic Procedure
Drug: Itraconazole
Drug: Placebo Administration
Other: Questionnaire Administration
Procedure: Radiofrequency Ablation

First Posted Date: 2024-12-13

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT06732388

Locations: 🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 4 locations

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

Phase 2

Not yet recruiting

Conditions: Metastatic Microsatellite Stable Colorectal Carcinoma
Refractory Microsatellite Stable Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v8

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: pH Low Insertion Peptide-exatecan Conjugate CBX-12
Procedure: X-Ray Imaging

First Posted Date: 2024-12-12

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT06730100

Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study

Recruiting

Conditions: Obesity
Type 2 Diabetes

First Posted Date: 2024-12-12

Last Posted Date: 2025-05-09

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 930

Registration Number: NCT06730113

Locations: 🇺🇸
Children's National Hospital (CNH), Washington, District of Columbia, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Phase 1

Recruiting

Conditions: Metastatic Colorectal Adenocarcinoma
Stage III Colorectal Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Unresectable Colorectal Adenocarcinoma

Interventions: Biological: Bevacizumab
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Emavusertib
Drug: Fluorouracil
Drug: Leucovorin Calcium
Procedure: Magnetic Resonance Imaging
Drug: Oxaliplatin
Procedure: Positron Emission Tomography

First Posted Date: 2024-11-20

Last Posted Date: 2025-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT06696768

Locations: 🇺🇸
Yale University Cancer Center LAO, New Haven, Connecticut, United States

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Not yet recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small Cell Lung
Non-Small Cell Lung Carcinoma
Non Small Cell Lung Cancer
Non Small Cell Lung Carcinoma

Interventions: Drug: azacytidine
Drug: carboplatin
Drug: paclitaxel
Drug: durvalumab
Drug: cisplatin
Drug: gemcitabine
Drug: pemetrexed

First Posted Date: 2024-11-19

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT06694454

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism

Not yet recruiting

Conditions: Healthy Volunteer
Obestity

First Posted Date: 2024-11-15

Last Posted Date: 2025-05-21

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 310

Registration Number: NCT06690294

Locations: 🇺🇸
National Institute of Diabetes and Digestive and Kidney Disorders (NIDDK), Phoenix, Arizona, United States

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Phase 2

Recruiting

Conditions: Gastrointestinal Carcinoma
Pancreatic Cancer
Hepatocellular Cancer
Cholangiocarcinoma
Duodenal Cancer
Colorectal Cancer
Small Bowel Cancer
Metastatic Cancers

Interventions: Biological: KRAS TCR-Transduced PBL
Drug: Aldesleukin
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-11-15

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 65

Registration Number: NCT06690281

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Decitabine and Cedazuridine
Drug: Venetoclax
Drug: Enasidenib

First Posted Date: 2024-11-04

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 93

Registration Number: NCT06672146

Locations: 🇺🇸
Augusta University Medical Center, Augusta, Georgia, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Saint Luke's Cancer Institute - Boise, Boise, Idaho, United States

and more 29 locations

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Phase 2

Recruiting

Conditions: Accelerated Phase Myeloproliferative Neoplasm
Essential Thrombocythemia
Myeloproliferative Neoplasm, Not Otherwise Specified
Blast Phase Myeloproliferative Neoplasm
Myelodysplastic/Myeloproliferative Neoplasm
Polycythemia Vera
Primary Myelofibrosis
Secondary Myelofibrosis

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Decitabine and Cedazuridine
Drug: Iadademstat

First Posted Date: 2024-10-28

Last Posted Date: 2025-05-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 62

Registration Number: NCT06661915

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center LAO, Duarte, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy